Cancer

OSE Immunotherapeutics Declares Presentation of TEDOVA Part 2 Topline Outcomes of Tedopi® in Ovarian Most cancers on the ASCO 2026 Assembly
Press Releases

OSE Immunotherapeutics Declares Presentation of TEDOVA Part 2 Topline Outcomes of Tedopi® in Ovarian Most cancers on the ASCO 2026 Assembly

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Significant Efficacy in Sufferers with HER2-Expressing, Recurrent Endometrial Most cancers
Press Releases

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Significant Efficacy in Sufferers with HER2-Expressing, Recurrent Endometrial Most cancers

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Section 2/3 Scientific Trial of SIL204 in Domestically Superior Pancreatic Most cancers
Stock Market

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Section 2/3 Scientific Trial of SIL204 in Domestically Superior Pancreatic Most cancers

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Part 2/3 Scientific Trial of SIL204 in Regionally Superior Pancreatic Most cancers
Stock Market

Silexion Therapeutics Receives Approval from Israeli Ministry of Well being to Provoke Part 2/3 Scientific Trial of SIL204 in Regionally Superior Pancreatic Most cancers

Kaida BioPharma Pronounces Govt Management Crew to Advance KAD-101, Constructed for the Ovarian Most cancers Hole
Press Releases

Kaida BioPharma Pronounces Govt Management Crew to Advance KAD-101, Constructed for the Ovarian Most cancers Hole